CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Which rewards card is better for travel? Explore options to maximize your travel benefits and choose the right card for you.
22,786 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
SpaceX gears up for the largest IPO in history on Nasdaq, while a 1:1 tokenized SpaceX equity trades on Solana. Backp...
A high-stakes moment for semiconductor supply and AI chip strategy has investors watching ASML. This analysis explain...
Banks are reviving sign-up bonuses on savings accounts as competition for deposits intensifies. This article breaks d...
Meta Platforms is advancing Arena, a stand-alone prediction markets app that would start with non-cash points and cou...
NASA gears up a bold robotic rescue to preserve the aging Swift Observatory, a move that could influence space-tech i...
Investors are asking why lucid stock jump this week. The answer lies in a fresh turnaround plan, improved liquidity h...
Blue Origin is pursuing a $130 billion private-market valuation, signaling a bold push by jeff bezos’s space company ...
Nvidia dominates today’s AI data centers, but the real threat to its throne may be a risk that sits in plain sight. T...
Applied Optoelectronics falls 12% as AI optics trade cools, with peers Lumentum and Coherent also lower. Analysts cit...
Intel stock has moved faster than its turnaround plan in many eyes. As Lip-Bu Tan reshapes the company, investors mus...
A veteran recruiter describes a rising problem: casual Zoom interviews with bathrobe moments and AI-assisted answers....